|
covid-19 |
54 |
|
humans |
48 |
|
adult |
46 |
|
sars-cov-2 |
39 |
|
systemic lupus erythematosus |
34 |
|
female |
33 |
|
middle aged |
30 |
|
male |
29 |
|
aged |
28 |
|
rheumatoid arthritis |
25 |
|
genome-wide association study |
22 |
|
prevalence |
20 |
|
public health |
20 |
|
complications |
19 |
|
sle |
19 |
|
asian continental ancestry group - genetics |
18 |
|
genetic predisposition to disease |
18 |
|
hong kong |
18 |
|
inflammation |
18 |
|
lupus nephritis |
18 |
|
spondyloarthritis |
17 |
|
adult learning principles |
16 |
|
collaborative practice |
16 |
|
epidemiology |
16 |
|
evaluation |
16 |
|
interprofessional education |
16 |
|
tuberculosis |
16 |
|
atherosclerosis |
15 |
|
cardiovascular diseases |
15 |
|
medical sciences |
15 |
|
asian |
14 |
|
association |
14 |
|
case-control studies |
14 |
|
chinese |
14 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
hong kong - epidemiology |
14 |
|
mortality |
14 |
|
quality of life |
14 |
|
china |
13 |
|
lupus erythematosus, systemic - genetics |
13 |
|
autoantibodies |
12 |
|
chronic diseases |
12 |
|
covid-19 vaccines |
12 |
|
disease activity |
12 |
|
endothelial progenitor cells |
12 |
|
ephrin-a2 - genetics |
12 |
|
health services |
12 |
|
innate immunity |
12 |
|
lupus erythematosus, systemic - genetics - immunology |
12 |
|
non-communicable diseases |
12 |
|
uhrf1bp1 |
12 |
|
adolescent |
11 |
|
antigens, cd3 - genetics |
11 |
|
autoantibodies - blood |
11 |
|
cd247 |
11 |
|
chemicals and cas registry numbers |
11 |
|
coronary artery disease |
11 |
|
gwas |
11 |
|
health economics |
11 |
|
model |
11 |
|
omicron |
11 |
|
pasc |
11 |
|
primary care |
11 |
|
aged, 80 and over |
10 |
|
autoimmune disorders |
10 |
|
axial spondyloarthritis |
10 |
|
bnt162b2 |
10 |
|
cells, cultured |
10 |
|
coronavac |
10 |
|
covid-19 vaccine |
10 |
|
cytokines |
10 |
|
inactivated vaccine |
10 |
|
incident cvd |
10 |
|
intracellular signaling peptides and proteins - genetics |
10 |
|
long covid |
10 |
|
lupus erythematosus, systemic - enzymology - genetics |
10 |
|
magnetic resonance imaging |
10 |
|
post-acute sequelae of sars-cov-2 |
10 |
|
post-covid cvd |
10 |
|
risk assessment |
10 |
|
antibodies, antinuclear - blood |
9 |
|
chest x-ray |
9 |
|
enzyme-linked immunosorbent assay |
9 |
|
health sciences |
9 |
|
hypersensitivity |
9 |
|
lupus |
9 |
|
lupus erythematosus |
9 |
|
medicine |
9 |
|
molnupiravir |
9 |
|
nirmatrelvir-ritonavir |
9 |
|
nomogram |
9 |
|
nursing |
9 |
|
pharmacy |
9 |
|
prediction model |
9 |
|
rheumatology |
9 |
|
risk factors |
9 |
|
severity of illness index |
9 |
|
systematic review |
9 |
|
undergraduate students |
9 |
|
viral disease |
9 |
|
waning vaccine effectiveness |
9 |
|
white cell count |
9 |
|
age-specific association |
8 |
|
allergy |
8 |
|
antibody response |
8 |
|
asymptomatic infection |
8 |
|
case study |
8 |
|
cluster analysis |
8 |
|
diabetes mellitus |
8 |
|
dna methylation |
8 |
|
dose-response relationship, drug |
8 |
|
double-blind method |
8 |
|
drug |
8 |
|
early |
8 |
|
genotype |
8 |
|
health-related quality of life |
8 |
|
hemoglobin a1c |
8 |
|
high-risk |
8 |
|
imaging |
8 |
|
indirect effect |
8 |
|
interferon beta-1b |
8 |
|
logistic models |
8 |
|
meta-analysis |
8 |
|
multi-detector computed tomography |
8 |
|
multiple organ complications |
8 |
|
multivariate analysis |
8 |
|
prediction |
8 |
|
primary care clinic |
8 |
|
remdesivir |
8 |
|
rheumatoid |
8 |
|
severity |
8 |
|
specialist outpatient clinics |
8 |
|
type 2 diabetes mellitus |
8 |
|
access to healthcare |
7 |
|
ankylosing spondylitis |
7 |
|
antigens, cd11b - genetics |
7 |
|
arterial calcification |
7 |
|
arthritisosteogenesis |
7 |
|
asian continental ancestry group |
7 |
|
asian continental ancestry group - ethnology - genetics |
7 |
|
autoimmunity |
7 |
|
bone–vascular axis |
7 |
|
calcification |
7 |
|
cardiovascular disease |
7 |
|
chronic respiratory disease |
7 |
|
conduction disorders |
7 |
|
diagnosis |
7 |
|
disease susceptibility |
7 |
|
epistasis |
7 |
|
eq-5d |
7 |
|
ets1 |
7 |
|
genome sequencing |
7 |
|
genomic diversity |
7 |
|
health status indicators |
7 |
|
healthcare system |
7 |
|
hong kong genome project |
7 |
|
hrqol |
7 |
|
hypertension |
7 |
|
il-17 |
7 |
|
immunocompromised host |
7 |
|
indirect impact |
7 |
|
infection |
7 |
|
interstitial lung disease |
7 |
|
long read genome sequencing |
7 |
|
lupus erythematosus, systemic - complications - physiopathology |
7 |
|
lupus erythematosus, systemic - ethnology - genetics |
7 |
|
lupus erythematosus, systemic - ethnology - immunology |
7 |
|
mri |
7 |
|
nephritis - ethnology - genetics |
7 |
|
oral health |
7 |
|
osteocalcin |
7 |
|
osteogenic endothelial progenitor cells |
7 |
|
population-based genome project |
7 |
|
precision medicine |
7 |
|
rare disease |
7 |
|
short read genome sequencing |
7 |
|
sjögren's syndrome |
7 |
|
spa |
7 |
|
systemic |
7 |
|
aging - immunology - metabolism |
6 |
|
animals |
6 |
|
ankylosing spondylitis disease activity index |
6 |
|
anti-inflammatory agents - pharmacology |
6 |
|
aorta, thoracic - pathology - radiography |
6 |
|
aortic diseases - epidemiology - radiography |
6 |
|
arthritis, rheumatoid - complications |
6 |
|
arthritis, rheumatoid - complications - immunology - physiopathology |
6 |
|
atherosclerosis - epidemiology - physiopathology - radiography |
6 |
|
atherosclerosis - epidemiology - radiography |
6 |
|
autoimmune disease |
6 |
|
blood |
6 |
|
bronchiectasis |
6 |
|
bronchiectasis - metabolism |
6 |
|
calcinosis - complications - epidemiology - radiography |
6 |
|
calcinosis - epidemiology - physiopathology - radiography |
6 |
|
calcinosis - etiology - radiography |
6 |
|
cardiovascular diseases - epidemiology - physiopathology - radiography |
6 |
|
cardiovascular event |
6 |
|
cardiovascular system - pathology - physiopathology - radiography |
6 |
|
carotid arteries - pathology - radiography |
6 |
|
carotid artery diseases - epidemiology - radiography |
6 |
|
carotid artery, common - radiography |
6 |
|
carrier proteins - blood - genetics |
6 |
|
cell composition |
6 |
|
cell lineage-specific |
6 |
|
cerebrovascular event |
6 |
|
child |
6 |
|
cohort studies |
6 |
|
computer tomography |
6 |
|
coronary artery calcium |
6 |
|
coronary artery disease - epidemiology - immunology - physiopathology |
6 |
|
coronary artery disease - etiology - radiography |
6 |
|
coronary vessels - pathology |
6 |
|
cross-over studies |
6 |
|
dendritic cells |
6 |
|
dental caries |
6 |
|
diffusion-weighted imaging |
6 |
|
drug modulation |
6 |
|
endothelium, vascular - immunology - pathology |
6 |
|
epithelial cells |
6 |
|
glucocorticoids - therapeutic use |
6 |
|
health status measures |
6 |
|
health surveys |
6 |
|
immunodeficiency |
6 |
|
immunosuppressive agents - adverse effects - therapeutic use |
6 |
|
incidence |
6 |
|
interleukin-6 |
6 |
|
interleukin-6 - biosynthesis |
6 |
|
linkage disequilibrium |
6 |
|
lupus erythematosus, systemic - complications |
6 |
|
lupus erythematosus, systemic - complications - drug therapy |
6 |
|
mesenchymal stem cells - immunology - pathology |
6 |
|
methylationepic |
6 |
|
muscarinic agonists - adverse effects - therapeutic use |
6 |
|
myocardial infarction |
6 |
|
nerve tissue proteins - genetics |
6 |
|
paediatric-onset |
6 |
|
patient satisfaction |
6 |
|
periodontal status |
6 |
|
phenotype |
6 |
|
polymorphism, single nucleotide - genetics |
6 |
|
prednisolone - therapeutic use |
6 |
|
protein-serine-threonine kinases - genetics |
6 |
|
quinuclidines - adverse effects - therapeutic use |
6 |
|
saliva |
6 |
|
salivary flow rate |
6 |
|
scleroderma, systemic - complications - radiography |
6 |
|
sjogren's syndrome - complications - ethnology |
6 |
|
sjogren's syndrome - psychology - rehabilitation |
6 |
|
stat4 transcription factor - genetics |
6 |
|
statistics, nonparametric |
6 |
|
stroke |
6 |
|
systemic lupus erythematosus (sle) |
6 |
|
systemic sclerosis |
6 |
|
t cells |
6 |
|
thiophenes - adverse effects - therapeutic use |
6 |
|
tomography, spiral computed |
6 |
|
vascular calcification |
6 |
|
xerostomia |
6 |
|
xerostomia - drug therapy - ethnology - etiology |
6 |
|
xerostomia - etiology - rehabilitation |
6 |
|
anaphylaxis |
5 |
|
arteries - pathology |
5 |
|
arthritis, rheumatoid - complications - pathology - physiopathology |
5 |
|
bath ankylosing spondylitis metrology index |
5 |
|
bdmards |
5 |
|
calcinosis - epidemiology - etiology - pathology |
5 |
|
calcinosis - pathology - radiography |
5 |
|
cardiovascular |
5 |
|
cardiovascular safety of biologics |
5 |
|
carrier proteins - genetics |
5 |
|
cell proliferation - drug effects |
5 |
|
classification criteria |
5 |
|
communication |
5 |
|
computed tomography |
5 |
|
coronary angiography |
5 |
|
coronary artery disease - complications - radiography |
5 |
|
coronary calcification |
5 |
|
corticosteroid |
5 |
|
cytotoxicity |
5 |
|
education, medical, undergraduate - methods |
5 |
|
genetics |
5 |
|
haplotypes |
5 |
|
health policy |
5 |
|
heart valve diseases - epidemiology - etiology - pathology |
5 |
|
high-sensitivity troponin i |
5 |
|
immunoglobulin g - biosynthesis |
5 |
|
infant, newborn |
5 |
|
jak inhibitors |
5 |
|
left ventricular longitudinal strain |
5 |
|
lupus erythematosus, systemic - blood - genetics |
5 |
|
lupus erythematosus, systemic - complications - pathology - physiopathology |
5 |
|
major adverse cardiovascular events |
5 |
|
medical education & training |
5 |
|
mental health |
5 |
|
mycobacterium |
5 |
|
mycobacterium infections, atypical - complications - diagnosis |
5 |
|
mycophenolic acid |
5 |
|
opportunistic infections - complications - diagnosis |
5 |
|
pharmacokinetics |
5 |
|
physician-patient relations |
5 |
|
polymorphism, genetic |
5 |
|
polymorphism, single nucleotide |
5 |
|
problem solving |
5 |
|
problem-based learning - methods |
5 |
|
prognosis |
5 |
|
promoter regions, genetic - genetics |
5 |
|
prospective studies |
5 |
|
real-world observational study |
5 |
|
regression analysis |
5 |
|
retrospective studies |
5 |
|
scleroderma, systemic - complications - pathology |
5 |
|
sjogren's syndrome |
5 |
|
subphenotype |
5 |
|
synovitis |
5 |
|
systemic calcified atherosclerosis |
5 |
|
time factors |
5 |
|
valvular calcification |
5 |
|
aeromonas - isolation & purification |
4 |
|
age distribution |
4 |
|
allergy centre |
4 |
|
allergy services |
4 |
|
anti-bacterial agents - therapeutic use |
4 |
|
anti-inflammatory agents, non-steroidal - therapeutic use |
4 |
|
antibodies, antiphospholipid - blood |
4 |
|
antigens, cd - metabolism |
4 |
|
antirheumatic agents |
4 |
|
arthritis, infectious - etiology |
4 |
|
arthritis, rheumatoid - complications - drug therapy |
4 |
|
arthroplasty, replacement, hip |
4 |
|
asas criteria |
4 |
|
asia pacific |
4 |
|
azathioprine - therapeutic use |
4 |
|
basophil activation test |
4 |
|
biological markers |
4 |
|
blotting, western |
4 |
|
calcitriol |
4 |
|
carcinoma, hepatocellular - blood - complications - genetics |
4 |
|
cardiovascular diseases - ethnology - etiology |
4 |
|
carotid intima-media thickness |
4 |
|
cervical cancer |
4 |
|
china - ethnology |
4 |
|
codon - genetics |
4 |
|
combined modality therapy |
4 |
|
corner inflammatory lesion |
4 |
|
cyclin-dependent kinase inhibitor p21 - biosynthesis - genetics |
4 |
|
cyclophosphamide - adverse effects - therapeutic use |
4 |
|
debridement |
4 |
|
disseminated intravascular coagulation - etiology |
4 |
|
endothelial dysfunction |
4 |
|
endothelium, vascular - metabolism - pathology |
4 |
|
estrogen replacement therapy |
4 |
|
fasciitis, necrotizing - drug therapy - etiology - surgery |
4 |
|
fatal outcome |
4 |
|
femur head necrosis - chemically induced - surgery |
4 |
|
fishes - microbiology |
4 |
|
follow-up studies |
4 |
|
fungal |
4 |
|
glycoproteins - metabolism |
4 |
|
gram-negative bacterial infections - drug therapy - etiology - surgery |
4 |
|
haplotype |
4 |
|
haplotypes - genetics |
4 |
|
hospitals, university |
4 |
|
hrct |
4 |
|
immunocompromised hosts, β-haemolytic streptococcus |
4 |
|
immunosuppressive agents - therapeutic use |
4 |
|
interferon regulatory factors - genetics |
4 |
|
interleukin 10 |
4 |
|
interleukin-10 - genetics |
4 |
|
kidney - pathology |
4 |
|
left ventricular function |
4 |
|
liver neoplasms - blood - complications - genetics |
4 |
|
lupus erythematosus, systemic |
4 |
|
lupus erythematosus, systemic - blood - immunology |
4 |
|
lupus erythematosus, systemic - epidemiology - genetics |
4 |
|
lupus nephritis - drug therapy |
4 |
|
mannose-binding lectins |
4 |
|
metabolic syndrome x - complications - ethnology |
4 |
|
modified new york criteria |
4 |
|
mycophenolic acid - adverse effects - analogs & derivatives - therapeutic use |
4 |
|
osteoarthritis |
4 |
|
outcome |
4 |
|
p21 |
4 |
|
penicillins |
4 |
|
peptides - metabolism |
4 |
|
perception |
4 |
|
peritonitis - blood - complications - genetics |
4 |
|
plant extracts - isolation & purification - pharmacology |
4 |
|
pneumonia |
4 |
|
point mutation - genetics |
4 |
|
prednisolone - adverse effects - therapeutic use |
4 |
|
pregnancy |
4 |
|
pregnancy outcome |
4 |
|
prevention |
4 |
|
prophylaxis |
4 |
|
pseudomonas infections - drug therapy - etiology - surgery |
4 |
|
questionnaires |
4 |
|
recurrence |
4 |
|
reishi - chemistry |
4 |
|
renal |
4 |
|
rheumatic diseases - complications - ethnology |
4 |
|
risk |
4 |
|
scleroderma, diffuse - complications - drug therapy |
4 |
|
sex distribution |
4 |
|
shock, septic - etiology |
4 |
|
sickness impact profile |
4 |
|
single nucleotide polymorphism |
4 |
|
skin - injuries |
4 |
|
skin transplantation |
4 |
|
stem cells - metabolism - pathology |
4 |
|
streptococcal infections - drug therapy - etiology - surgery |
4 |
|
surgical wound infection - etiology |
4 |
|
susceptibility |
4 |
|
toll-like receptor 7 |
4 |
|
training |
4 |
|
treatment outcome |
4 |
|
uveitis |
4 |
|
abortion, habitual - complications - ethnology - immunology |
3 |
|
adrenal cortex hormones - administration & dosage - adverse effects |
3 |
|
adrenomedullin - blood |
3 |
|
age |
3 |
|
age factors |
3 |
|
age of onset |
3 |
|
alanine transaminase - blood |
3 |
|
alleles |
3 |
|
amoxicillin - therapeutic use |
3 |
|
analysis of variance |
3 |
|
anti-mbl antibodies |
3 |
|
anti-β 2-glycoprotein i antibodies |
3 |
|
antibiotic prophylaxis |
3 |
|
antibodies, viral - blood |
3 |
|
anticardiolipin antibodies |
3 |
|
antigen presentation |
3 |
|
antigens, cd |
3 |
|
antigens, surface - genetics |
3 |
|
antioxidants - pharmacology |
3 |
|
antiphospholipid syndrome |
3 |
|
antirheumatic agents - toxicity |
3 |
|
antitubercular agents - therapeutic use |
3 |
|
apoptosis regulatory proteins |
3 |
|
apparent diffusion coefficient |
3 |
|
apparent weighted coefficient |
3 |
|
arthritis, rheumatoid - drug therapy |
3 |
|
arthritis, rheumatoid - drug therapy - immunology - pathology |
3 |
|
arthritis, rheumatoid - drug therapy - virology |
3 |
|
arthritis, rheumatoid - ethnology - genetics |
3 |
|
arthritis, rheumatoid - genetics |
3 |
|
ascending |
3 |
|
ascomycota - chemistry |
3 |
|
asian continental ancestry group - statistics & numerical data |
3 |
|
autoantibodies - analysis |
3 |
|
bacterial infections - ethnology - immunology |
3 |
|
biological markers - blood |
3 |
|
biopsy |
3 |
|
blood platelets - immunology |
3 |
|
bone density - drug effects |
3 |
|
bone density - drug effects - physiology |
3 |
|
bone diseases, metabolic - chemically induced - drug therapy - etiology |
3 |
|
bone marrow cells - pathology |
3 |
|
bone mineral density |
3 |
|
brain diseases - diagnosis |
3 |
|
calcitriol - administration & dosage |
3 |
|
calcitriol - therapeutic use |
3 |
|
calcium |
3 |
|
calcium - blood |
3 |
|
calcium - urine |
3 |
|
calcium channel agonists - therapeutic use |
3 |
|
cell communication |
3 |
|
cell culture techniques |
3 |
|
cell line |
3 |
|
cell survival - drug effects |
3 |
|
challenging variants |
3 |
|
chemoprophylaxis |
3 |
|
chinese herb |
3 |
|
chronic osteoarthritis |
3 |
|
clarithromycin - therapeutic use |
3 |
|
clec16a |
3 |
|
cognitive dysfunction |
3 |
|
collectins |
3 |
|
complement deficiency |
3 |
|
connective tissue disease |
3 |
|
corpus callosum |
3 |
|
corticotropin-releasing hormone - genetics |
3 |
|
crispr/cas9 |
3 |
|
cytokines - biosynthesis |
3 |
|
cytokines - immunology |
3 |
|
cytotoxic |
3 |
|
dementia |
3 |
|
dendritic cells - drug effects - pathology - physiology |
3 |
|
dendritic cells - immunology |
3 |
|
dermatomyositis |
3 |
|
diagnosis, differential |
3 |
|
diffusion weighted imaging |
3 |
|
disease modifying anti-rheumatic drugs |
3 |
|
disease modifying drugs |
3 |
|
disease progression |
3 |
|
disease susceptibility - ethnology - immunology |
3 |
|
dna primers - chemistry |
3 |
|
doublecortin |
3 |
|
drug therapy, combination - therapeutic use |
3 |
|
drug-induced liver injury - virology |
3 |
|
drugs, chinese herbal - pharmacology |
3 |
|
duodenal ulcer - prevention & control |
3 |
|
dyspepsia - etiology |
3 |
|
electromyography |
3 |
|
elisa |
3 |
|
endemic diseases |
3 |
|
endoscopy, gastrointestinal |
3 |
|
essential fatty acids |
3 |
|
european continental ancestry group |
3 |
|
evoked potentials, motor - physiology |
3 |
|
expanded potential |
3 |
|
false positive reactions |
3 |
|
family health |
3 |
|
fibroblasts - cytology - drug effects - metabolism |
3 |
|
flow cytometry |
3 |
|
fungal compounds |
3 |
|
gain of function |
3 |
|
ganoderma lucidum |
3 |
|
gene editing |
3 |
|
gene expression - drug effects |
3 |
|
gene expression regulation |
3 |
|
gene frequency |
3 |
|
genetic linkage |
3 |
|
gfap |
3 |
|
glaucoma - diagnosis |
3 |
|
glucocorticoid |
3 |
|
glucocorticoids - adverse effects |
3 |
|
gout |
3 |
|
health status |
3 |
|
helicobacter infections - drug therapy |
3 |
|
helicobacter pylori |
3 |
|
hepatitis b virus |
3 |
|
hepatitis b, chronic - complications |
3 |
|
hepatitis c virus |
3 |
|
hepatitis c, chronic - complications |
3 |
|
hepatotoxicity |
3 |
|
herbal medicine |
3 |
|
hereditary sensory and autonomic neuropathies - blood - diagnosis |
3 |
|
hereditary sensory and motor neuropathy - blood - diagnosis |
3 |
|
hormonal replacement therapy |
3 |
|
hospitalization |
3 |
|
hypertension, pulmonary - blood - etiology |
3 |
|
hypertension, pulmonary - drug therapy - etiology |
3 |
|
hypogonadism - complications |
3 |
|
iba-1 |
3 |
|
iloprost - administration and dosage |
3 |
|
immune mediated diseases |
3 |
|
immune response |
3 |
|
immune-complex |
3 |
|
immunocompromised host - drug effects - immunology |
3 |
|
immunocompromised host - immunology |
3 |
|
immunoglobulin g - blood |
3 |
|
immunoglobulin m - biosynthesis |
3 |
|
immunoglobulin m - blood |
3 |
|
immunologic factors - chemistry - pharmacology |
3 |
|
immunomodulation |
3 |
|
immunomodulatory drugs |
3 |
|
immunosuppressant |
3 |
|
immunosuppression |
3 |
|
inborn errors of immunity |
3 |
|
inducible nitric oxide synthase |
3 |
|
infliximab |
3 |
|
interferon type i - immunology |
3 |
|
intracellular signaling peptides and proteins |
3 |
|
isoniazid - therapeutic use |
3 |
|
janus activating kinase (jak) inhibitor |
3 |
|
kidney failure, chronic - etiology |
3 |
|
knowledge |
3 |
|
late-onset |
3 |
|
liver - drug effects - enzymology - virology |
3 |
|
lod score |
3 |
|
longitudinal studies |
3 |
|
lung diseases, interstitial - blood - etiology |
3 |
|
lupus erythematosus, systemic - blood - complications |
3 |
|
lupus erythematosus, systemic - blood - complications - drug therapy - ethnology |
3 |
|
lupus erythematosus, systemic - blood - immunology - pathology |
3 |
|
lupus erythematosus, systemic - complications - drug therapy - epidemiology - immunology |
3 |
|
lupus erythematosus, systemic - complications - ethnology - immunology |
3 |
|
lupus erythematosus, systemic - drug therapy |
3 |
|
lupus erythematosus, systemic - immunology - pathology |
3 |
|
lupus erythematosus, systemic - pathology - physiopathology |
3 |
|
lymphocyte culture test, mixed |
3 |
|
lymphocytes - drug effects |
3 |
|
lyprinol® |
3 |
|
macrophages - drug effects - enzymology |
3 |
|
mannose-binding lectin - blood - genetics |
3 |
|
mannose-binding lectins - deficiency - immunology |
3 |
|
mbl deficiency |
3 |
|
mda5 |
3 |
|
medicinal fungal compounds |
3 |
|
medicine, chinese traditional |
3 |
|
mesenchymal stem cells |
3 |
|
metronidazole - therapeutic use |
3 |
|
microrna |
3 |
|
micrornas |
3 |
|
micrornas - genetics |
3 |
|
microsatellite repeats |
3 |
|
mitogens - metabolism |
3 |
|
monocytes - drug effects - metabolism |
3 |
|
mood disorder |
3 |
|
mutation - genetics |
3 |
|
mycobacterial infection |
3 |
|
mycobacterium tuberculosis - isolation & purification |
3 |
|
myeloid cells - immunology |
3 |
|
natural remedies |
3 |
|
neurogenesis |
3 |
|
neuroinflammation |
3 |
|
neuropathy |
3 |
|
neuropsychiatric lupus |
3 |
|
neutrophils - immunology |
3 |
|
nf-kappa b - metabolism |
3 |
|
nf-κb |
3 |
|
nitrates - analysis - metabolism |
3 |
|
nitric oxide |
3 |
|
nitric oxide synthase |
3 |
|
nitric oxide synthase type ii - antagonists & inhibitors - genetics |
3 |
|
nitrites - analysis - metabolism |
3 |
|
nocardia |
3 |
|
nod2 signaling adaptor protein |
3 |
|
non-coding variants |
3 |
|
opportunistic infections - genetics - immunology |
3 |
|
osteopenia |
3 |
|
osteoporosis |
3 |
|
osteoporosis - chemically induced - drug therapy - physiopathology |
3 |
|
oxidative stress |
3 |
|
perna canaliculus |
3 |
|
personalized |
3 |
|
pestalotiopsis leucothës |
3 |
|
phosphorylation |
3 |
|
plasmacytoid dendritic cells |
3 |
|
pneumomediastinum |
3 |
|
polymorphism |
3 |
|
prednisolone - adverse effects |
3 |
|
pregnancy complications |
3 |
|
pregnancy complications, hematologic - ethnology - immunology |
3 |
|
premenopause - drug effects - metabolism |
3 |
|
primary care physicians |
3 |
|
programmed cell death 1 receptor |
3 |
|
prostacyclin |
3 |
|
prostaglandin |
3 |
|
proteoglycans - pharmacology - therapeutic use |
3 |
|
pseudogenes |
3 |
|
rare diseases |
3 |
|
raynaud disease - blood - etiology |
3 |
|
receptors, interleukin-2 - biosynthesis |
3 |
|
reference values |
3 |
|
referral strategy |
3 |
|
regulatory t cell |
3 |
|
repeat expansions |
3 |
|
reverse transcriptase polymerase chain reaction |
3 |
|
rna, messenger - analysis - metabolism |
3 |
|
scleroderma, systemic - blood - complications - physiopathology |
3 |
|
scleroderma, systemic - complications - mortality |
3 |
|
secondary pulmonary hypertension |
3 |
|
short tau inversion recovery sequence |
3 |
|
signal transducer and activator of transcription 1 (stat1) |
3 |
|
socioeconomic factors |
3 |
|
spliced variants |
3 |
|
spondyloarthritis research consortium of canada mri |
3 |
|
stem cell |
3 |
|
steroid |
3 |
|
steroids - adverse effects |
3 |
|
stomach ulcer - prevention & control |
3 |
|
structural variants |
3 |
|
subventricular zone |
3 |
|
superoxides - analysis - metabolism |
3 |
|
sweden |
3 |
|
symptoms |
3 |
|
synovial fibroblast |
3 |
|
synovial membrane - cytology |
3 |
|
telomerase |
3 |
|
tetradecanoylphorbol acetate - pharmacology |
3 |
|
th1 cells - drug effects - metabolism |
3 |
|
th2 cells - drug effects - metabolism |
3 |
|
thrombosis |
3 |
|
thrombosis - complications - ethnology - immunology |
3 |
|
tolerogenicity |
3 |
|
toll-like receptors |
3 |
|
traditional chinese medicine |
3 |
|
treatment recommendation |
3 |
|
tripterygium - microbiology |
3 |
|
tripterygium wilfordii |
3 |
|
triptolide |
3 |
|
tuberculoma, intracranial - diagnosis |
3 |
|
tuberculosis - complications - epidemiology - immunology - prevention & control |
3 |
|
type-i interferon |
3 |
|
urate-lowering therapy |
3 |
|
vasodilator agents - administration and dosage |
3 |
|
vitamin d3 |
3 |
|
whole genome sequencing |
3 |
|
young hypogonadal women |
3 |
|
activities of daily living |
2 |
|
activities of daily living - classification |
2 |
|
acute generalized exanthematous pustulosis |
2 |
|
adrenaline autoinjector |
2 |
|
adrenomedullin |
2 |
|
allergology and immunology |
2 |
|
alternative therapies |
2 |
|
anemia, hemolytic - blood - complications |
2 |
|
anemia, hemolytic, autoimmune - ethnology - etiology |
2 |
|
anti-bacterial agents |
2 |
|
anti-inflammatory agents - therapeutic use |
2 |
|
anti-proliferative activity |
2 |
|
antibiotics |
2 |
|
antibodies, antinuclear - analysis |
2 |
|
antibody specificity - immunology |
2 |
|
antifungal agents - therapeutic use |
2 |
|
antigen presenting cells |
2 |
|
antigens, cd - biosynthesis |
2 |
|
antigens, cd - immunology |
2 |
|
antigens, cd34 - biosynthesis |
2 |
|
antigens, viral - blood |
2 |
|
antihypertensive agents - therapeutic use |
2 |
|
anxiety disorder |
2 |
|
apoptosis - immunology |
2 |
|
arthritis |
2 |
|
arthritis, psoriatic - diagnosis - immunology - microbiology |
2 |
|
arthritis, reactive - diagnosis - immunology - microbiology |
2 |
|
arthritis, rheumatoid - diagnosis - physiopathology |
2 |
|
arthrocentesis |
2 |
|
arthroplasty |
2 |
|
arthroplasty, replacement - methods |
2 |
|
asdas |
2 |
|
asia |
2 |
|
attitude of health personnel |
2 |
|
autoantibodies - analysis - genetics |
2 |
|
autoantigens - immunology |
2 |
|
autoimmune diseases |
2 |
|
autoimmune thyroid disease |
2 |
|
autophagy |
2 |
|
avascular necrosis |
2 |
|
avian proteins - metabolism |
2 |
|
azathioprine (aza) |
2 |
|
azathioprine - adverse effects |
2 |
|
b cells |
2 |
|
back pain |
2 |
|
basdai |
2 |
|
bcl-6 |
2 |
|
beta-lactam |
2 |
|
beta-lactams |
2 |
|
biological markers - metabolism |
2 |
|
blood pressure - drug effects |
2 |
|
blood proteins - pharmacology |
2 |
|
bone marrow cells - immunology - metabolism |
2 |
|
bone morrow cd34+ cells |
2 |
|
c6 |
2 |
|
capsid proteins |
2 |
|
cardiovascular diseases - diagnosis - etiology |
2 |
|
case report |
2 |
|
cause of death |
2 |
|
cd103 |
2 |
|
cd166 |
2 |
|
cd69 |
2 |
|
cell adhesion molecules, neuronal - biosynthesis |
2 |
|
cell division - immunology |
2 |
|
cell separation |
2 |
|
cell shape |
2 |
|
cell surface markers |
2 |
|
cellular function |
2 |
|
chi-square distribution |
2 |
|
china - epidemiology |
2 |
|
chondritis |
2 |
|
clinical article |
2 |
|
complement |
2 |
|
complement c3 - analysis |
2 |
|
complementary therapies - adverse effects - economics - utilization |
2 |
|
confocal microscopy |
2 |
|
continental population groups - genetics |
2 |
|
cost |
2 |
|
costs |
2 |
|
costs and cost analysis |
2 |
|
creatinine - blood |
2 |
|
cremα |
2 |
|
cross-cultural comparison |
2 |
|
cross-sectional studies |
2 |
|
crosscultural validation |
2 |
|
cryptococcaemia |
2 |
|
cryptococcal meningitis |
2 |
|
ctfh |
2 |
|
cyclophosphamide - administration & dosage - adverse effects |
2 |
|
cyclophosphamide - administration & dosage - therapeutic use |
2 |
|
cytokines - blood - immunology |
2 |
|
cytomegalovirus - immunology - isolation & purification |
2 |
|
damage |
2 |
|
dapsone - adverse effects |
2 |
|
deficiency |
2 |
|
dendritic cells - cytology - immunology |
2 |
|
dendritic cells - immunology - metabolism - pathology |
2 |
|
depressive disorder |
2 |
|
differentiation |
2 |
|
dle |
2 |
|
dmard |
2 |
|
dnmt3a |
2 |
|
docosahexaenoic acids |
2 |
|
drug combinations |
2 |
|
drug formulation |
2 |
|
drug hypersensitivity |
2 |
|
drug treatment |
2 |
|
drug-induced liver injury - etiology - pathology |
2 |
|
dysmotility |
2 |
|
echocardiography |
2 |
|
eicosapentaenoic acid |
2 |
|
endophytic fungi |
2 |
|
endothelin-1 |
2 |
|
epidemiology < systemic lupus erythematosus |
2 |
|
ethnic groups - genetics |
2 |
|
exacerbation |
2 |
|
excipient allergy |
2 |
|
exercise tolerance |
2 |
|
fatigue |
2 |
|
fetal outcome |
2 |
|
financing, personal - statistics & numerical data |
2 |
|
functional status |
2 |
|
fungal infection |
2 |
|
fungi - isolation & purification |
2 |
|
gastrointestinal agents - therapeutic use |
2 |
|
gastrointestinal hemorrhage - epidemiology - etiology |
2 |
|
gender |
2 |
|
genetic predisposition to disease - ethnology |
2 |
|
growth inhibitors - isolation & purification - pharmacology |
2 |
|
h3k4me3 |
2 |
|
herpes zoster |
2 |
|
herpesvirus 4, human - immunology - isolation & purification - physiology |
2 |
|
histone modifications |
2 |
|
hormone |
2 |
|
hospital anxiety and depression scale |
2 |
|
human papilloma virus |
2 |
|
hydronephrosis - etiology |
2 |
|
hypertension, pulmonary - complications - drug therapy |
2 |
|
il-21 |
2 |
|
il-9 |
2 |
|
ileal diseases - diagnosis - drug therapy - etiology |
2 |
|
immunization |
2 |
|
immunoblotting |
2 |
|
immunoelectrophoresis |
2 |
|
immunoglobulin therapy |
2 |
|
immunoglobulins - immunology |
2 |
|
immunomagnetic separation |
2 |
|
immunosuppressive agents - administration & dosage - adverse effects |
2 |
|
immunosuppressive therapy |
2 |
|
influenza |
2 |
|
interferon-gamma - blood |
2 |
|
interferon-γ |
2 |
|
interleukin-17 - blood - immunology |
2 |
|
interleukin-18 receptor accessory protein |
2 |
|
interleukin-23 - blood - immunology |
2 |
|
interstitial cystitis |
2 |
|
intestinal pseudo-obstruction - diagnosis - drug therapy - etiology |
2 |
|
intestinal vasculitis |
2 |
|
isoelectric focusing |
2 |
|
janus kinase |
2 |
|
joint replacement |
2 |
|
kidney diseases - ethnology - etiology |
2 |
|
kienbock |
2 |
|
lau, c.s. |
2 |
|
leukemia, myelocytic, acute - chemically induced |
2 |
|
leukocytes, mononuclear - cytology - drug effects - physiology |
2 |
|
liver - drug effects - pathology |
2 |
|
long-term care |
2 |
|
low disease activity |
2 |
|
lunate |
2 |
|
lunatomalacia |
2 |
|
lupus anticoagulant |
2 |
|
lupus erythematosus, discoid - ethnology - etiology |
2 |
|
lupus erythematosus, systemic - blood |
2 |
|
lupus erythematosus, systemic - blood - immunology - physiopathology |
2 |
|
lupus erythematosus, systemic - complications - diagnosis - epidemiology - genetics - immunology |
2 |
|
lupus erythematosus, systemic - complications - immunology |
2 |
|
lupus erythematosus, systemic - epidemiology |
2 |
|
lupus erythematosus, systemic - epidemiology - microbiology |
2 |
|
lupus erythematosus, systemic - ethnology - genetics - physiopathology |
2 |
|
lupus erythematosus, systemic - immunology - metabolism - pathology |
2 |
|
lupus erythematosus, systemic - virology |
2 |
|
lupus low disease activity state |
2 |
|
lupus nephritis - blood - immunology - pathology |
2 |
|
lupus nephritis - complications |
2 |
|
lupus nephritis - drug therapy - pathology |
2 |
|
lupus nephritis - genetics - physiopathology |
2 |
|
lupus nephritis - pathology |
2 |
|
lupus vasculitis, central nervous system - complications |
2 |
|
lupus vasculitis, central nervous system - immunology |
2 |
|
lymphocytes - cytology - immunology |
2 |
|
macrophages - immunology |
2 |
|
macrophages - pathology |
2 |
|
maternal outcome |
2 |
|
membrane glycoproteins - immunology |
2 |
|
men |
2 |
|
meningitis, cryptococcal - complications - diagnosis - drug therapy |
2 |
|
mesenchymal stem cells (mscs) |
2 |
|
methotrexate |
2 |
|
mitogen-activated protein kinase |
2 |
|
mok, m.y. |
2 |
|
morbidity |
2 |
|
mtor signaling |
2 |
|
myeloid cells - cytology - immunology |
2 |
|
myeloid dendritic cell |
2 |
|
necrosis |
2 |
|
neoplasms, second primary - chemically induced |
2 |
|
neopterin |
2 |
|
neopterin - blood |
2 |
|
neutrophils - pathology |
2 |
|
nocardia infections - epidemiology |
2 |
|
opportunistic infection |
2 |
|
opportunistic infections - epidemiology |
2 |
|
osteoarthritis - diagnosis - epidemiology - surgery |
2 |
|
osteoarthritis - diagnosis - physiopathology |
2 |
|
osteoarthritis - economics - epidemiology |
2 |
|
osteoarthritis - economics - epidemiology - therapy |
2 |
|
osteoarthritis, hip - diagnosis - epidemiology - surgery |
2 |
|
osteoarthritis, knee - diagnosis - epidemiology - surgery |
2 |
|
osteochondritis - complications - immunology - radiography |
2 |
|
outcome measures |
2 |
|
outcomes measures |
2 |
|
outpatients |
2 |
|
paralytic ileus |
2 |
|
pathogenesis of pulmonary hypertension |
2 |
|
patient global assessment |
2 |
|
patient-reported outcomes |
2 |
|
penicillin |
2 |
|
peptides - blood |
2 |
|
perioperative |
2 |
|
peripheral blood mononuclear cells |
2 |
|
phagocytosis - drug effects - immunology |
2 |
|
physician global assessment |
2 |
|
plant structures |
2 |
|
pneumococcal |
2 |
|
pneumonia - etiology |
2 |
|
polymorphism, genetic - genetics |
2 |
|
polymyositis - complications |
2 |
|
postmenopause |
2 |
|
predictors |
2 |
|
prednisone - therapeutic use |
2 |
|
primary antibody deficiency |
2 |
|
probability |
2 |
|
proliferating cell nuclear antigen - immunology |
2 |
|
promoter regions, genetic |
2 |
|
protein kinase inhibitor |
2 |
|
protein-losing enteropathies - etiology |
2 |
|
psoriatic arthritis |
2 |
|
pulmonary hypertension |
2 |
|
quantitative proteomics |
2 |
|
references (29) view in table layout |
2 |
|
reproducibility of results |
2 |
|
rheumatism |
2 |
|
rheumatology - methods |
2 |
|
ribonucleoproteins - immunology |
2 |
|
ribonucleoproteins, small nuclear |
2 |
|
rna, small cytoplasmic |
2 |
|
safety |
2 |
|
scle |
2 |
|
secondary antibody deficiency |
2 |
|
sensitivity and specificity |
2 |
|
serositis |
2 |
|
serositis - etiology |
2 |
|
set1 |
2 |
|
sex |
2 |
|
sex characteristics |
2 |
|
sf-36 |
2 |
|
sf-36v2 |
2 |
|
short tau inversion recovery (stir) image |
2 |
|
sjogren's syndrome - complications - diagnosis |
2 |
|
sjogren's syndrome - drug therapy - pathology |
2 |
|
skin psoriasis |
2 |
|
small non-coding rnas |
2 |
|
snrnp core proteins |
2 |
|
social work - economics |
2 |
|
spinal mobility |
2 |
|
spine |
2 |
|
spleen tyrosine kinase |
2 |
|
spondylitis, ankylosing - classification - diagnosis - physiopathology |
2 |
|
spondylitis, ankylosing - diagnosis - immunology - microbiology |
2 |
|
spondyloarthropathies |
2 |
|
spondyloarthropathy |
2 |
|
still's disease, adult-onset - complications - drug therapy |
2 |
|
stomach ulcer - epidemiology - etiology |
2 |
|
sulfonamides - therapeutic use |
2 |
|
survival |
2 |
|
survival rate |
2 |
|
syndrome |
2 |
|
systemic lupus erythematous |
2 |
|
t-follicular helper |
2 |
|
tet2 |
2 |
|
th1 cells - immunology |
2 |
|
th2 cells - immunology |
2 |
|
th9 |
2 |
|
threonine-trna ligase - immunology |
2 |
|
thrombocytopenia - complications |
2 |
|
thrombosis - ethnology - etiology |
2 |
|
toll-like receptor 9 |
2 |
|
transcription factor |
2 |
|
treatment target |
2 |
|
treatments |
2 |
|
tripterygium |
2 |
|
trm cells |
2 |
|
tryptase |
2 |
|
type i interferon |
2 |
|
university department of medicine, queen mary hospital, pokfulam road, hong kong, hong kong
© copyright 2007 elsevier b.v., all rights reserved. |
2 |
|
vasculitis - complications - immunology |
2 |
|
vasculopathy |
2 |
|
virus replication |
2 |
|
womac |
2 |
|
world health |
2 |
|
wrist - radiography |
2 |
|
© medline is the source for the citation and abstract of this record. |
2 |
|
acidosis - etiology - prevention & control |
1 |
|
acute disease |
1 |
|
acute-phase reaction - complications - immunology |
1 |
|
adenosine diphosphate - pharmacology |
1 |
|
administration, oral |
1 |
|
adult still's disease |
1 |
|
african continental ancestry group - genetics |
1 |
|
amenorrhea - chemically induced |
1 |
|
amino acid sequence |
1 |
|
androgen |
1 |
|
anemia - etiology - prevention & control |
1 |
|
anemia, hemolytic - epidemiology - immunology |
1 |
|
angioplasty, balloon - adverse effects |
1 |
|
ankylosing spondylitis (as) |
1 |
|
anti-infective agents - adverse effects |
1 |
|
anti-inflammatory agents, non-steroidal - adverse effects - therapeutic use |
1 |
|
anti-malarials |
1 |
|
antibodies, antinuclear - blood - drug effects |
1 |
|
antibodies, antinuclear - blood - immunology |
1 |
|
antibodies, antinuclear - immunology |
1 |
|
antibody formation |
1 |
|
anticardiolipin |
1 |
|
antigens, cd - analysis |
1 |
|
antigens, cd5 |
1 |
|
antigens, cd5 - metabolism |
1 |
|
antineoplastic agents - administration & dosage - adverse effects - therapeutic use |
1 |
|
antiphospholipid |
1 |
|
antirheumatic agents - adverse effects |
1 |
|
antirheumatic agents - adverse effects - therapeutic use |
1 |
|
antirheumatic agents - therapeutic use |
1 |
|
aortitis |
1 |
|
apoptosis |
1 |
|
arachidonic acid - blood |
1 |
|
arteriosclerosis - complications |
1 |
|
arthritis, rheumatoid - blood |
1 |
|
arthritis, rheumatoid - blood - complications |
1 |
|
arthritis, rheumatoid - blood - immunology |
1 |
|
arthritis, rheumatoid - complications - radiography |
1 |
|
arthritis, rheumatoid - drug therapy - epidemiology |
1 |
|
arthritis, rheumatoid - drug therapy - physiopathology |
1 |
|
arthritis, rheumatoid - genetics - pathology |
1 |
|
asia - epidemiology |
1 |
|
asia pacific region |
1 |
|
asia, southeastern |
1 |
|
atrial fibrillation - chemically induced - epidemiology |
1 |
|
atrial natriuretic factor - administration & dosage - pharmacology |
1 |
|
attitude to health |
1 |
|
attitude to illness |
1 |
|
autoantibodies - biosynthesis |
1 |
|
autoantibodies - blood - immunology |
1 |
|
autoantibodies - immunology |
1 |
|
autoantibodies - metabolism |
1 |
|
autoantigens |
1 |
|
autoimmune |
1 |
|
autoimmune diseases - blood - immunology |
1 |
|
autoimmune diseases - physiopathology - therapy |
1 |
|
avascular bone necrosis |
1 |
|
azathioprine - administration & dosage |
1 |
|
azathioprine - administration & dosage - therapeutic use |
1 |
|
b-lymphocytes |
1 |
|
b-lymphocytes - immunology |
1 |
|
base sequence |
1 |
|
bayes theorem |
1 |
|
behaviour |
1 |
|
behcet's disease |
1 |
|
behçet's disease |
1 |
|
biologic |
1 |
|
biological assay - methods |
1 |
|
biological disease‐modifying antirheumatic drugs |
1 |
|
biological markers - analysis |
1 |
|
biological therapy |
1 |
|
biomedical research |
1 |
|
blood platelets - drug effects |
1 |
|
blood platelets - drug effects - physiology |
1 |
|
body temperature - physiology |
1 |
|
bone density conservation agents - administration & dosage - therapeutic use |
1 |
|
bone density conservation agents - pharmacology - therapeutic use |
1 |
|
bone density conservation agents - therapeutic use |
1 |
|
bone marrow transplantation - adverse effects |
1 |
|
brachial artery - physiopathology |
1 |
|
breast feeding - adverse effects |
1 |
|
burden |
1 |
|
cardiovascular diseases - complications |
1 |
|
cardiovascular diseases - etiology - prevention & control |
1 |
|
cardiovascular diseases - prevention & control |
1 |
|
carer reported |
1 |
|
cell adhesion |
1 |
|
central nervous system |
1 |
|
cerebrovascular disorders - epidemiology |
1 |
|
child, preschool |
1 |
|
choice behavior |
1 |
|
chondroitin sulfate |
1 |
|
chondroitin sulfates - adverse effects - therapeutic use |
1 |
|
chromosome mapping |
1 |
|
chromosomes, human, pair 1 - genetics |
1 |
|
chromosomes, human, pair 16 - genetics |
1 |
|
chromosomes, human, pair 20 - genetics |
1 |
|
cinnamaldehyde |
1 |
|
clinical feature |
1 |
|
clinical laboratory techniques - methods |
1 |
|
clinical trial |
1 |
|
cognition disorders - epidemiology |
1 |
|
cohort study |
1 |
|
cold temperature |
1 |
|
collagen - pharmacology |
1 |
|
community carecorona |
1 |
|
comorbidity |
1 |
|
complement c3 - drug effects - metabolism |
1 |
|
complement c4 - drug effects - metabolism |
1 |
|
complication |
1 |
|
connective tissue diseases - complications |
1 |
|
connective tissue disorder |
1 |
|
constriction, pathologic - blood |
1 |
|
contraception |
1 |
|
corticotropin-releasing hormone |
1 |
|
cost of illness |
1 |
|
cox-2 |
1 |
|
crithidia - chemistry - immunology |
1 |
|
cultural factor |
1 |
|
cushing syndrome - chemically induced |
1 |
|
cutaneous lupus erythematosus |
1 |
|
cyclo-oxygenase inhibitors |
1 |
|
cyclooxygenase 2 inhibitors - adverse effects |
1 |
|
cyclophosphamide |
1 |
|
cyclophosphamide - adverse effects |
1 |
|
cyclophosphamide - therapeutic use |
1 |
|
cytokine receptors |
1 |
|
daily hemodialysis (hd) |
1 |
|
dapsone |
1 |
|
das |
1 |
|
data interpretation, statistical |
1 |
|
deceased donor |
1 |
|
department of medicine, 4th floor, professional block, queen mary hospital, pokfulam, hong kong
© copyright 2007 elsevier b.v., all rights reserved. |
1 |
|
dialysis |
1 |
|
diclofenac - adverse effects |
1 |
|
dietary supplement |
1 |
|
dietary supplements |
1 |
|
dietary supplements - adverse effects |
1 |
|
dioxanes - pharmacology |
1 |
|
diphosphonates - administration & dosage - therapeutic use |
1 |
|
diphosphonates - adverse effects |
1 |
|
diphosphonates - adverse effects - therapeutic use |
1 |
|
diphosphonates - pharmacology - therapeutic use |
1 |
|
dipyridamole |
1 |
|
dipyridamole - pharmacology |
1 |
|
dipyridamole - therapeutic use |
1 |
|
disaster planning |
1 |
|
discontinuation |
1 |
|
disease aetiology and pathogenesis |
1 |
|
disease patterns |
1 |
|
disease‐modifying antirheumatic drugs |
1 |
|
dmards |
1 |
|
dna |
1 |
|
dna - immunology |
1 |
|
dna primers - genetics |
1 |
|
dna, single-stranded - immunology |
1 |
|
docosahexaenoic acids - blood |
1 |
|
docosahexaenoic acids - therapeutic use |
1 |
|
donation |
1 |
|
dose–response relationship |
1 |
|
down-titration |
1 |
|
drug administration schedule |
1 |
|
drug cost |
1 |
|
drug dose regimen |
1 |
|
drug hypersensitivity - etiology - pathology |
1 |
|
drug industry |
1 |
|
drug potentiation |
1 |
|
drug safety |
1 |
|
drug therapy, combination |
1 |
|
drug tolerance |
1 |
|
editorial |
1 |
|
editorial policies |
1 |
|
education, medical, continuing |
1 |
|
eicosanoids, prostaglandins |
1 |
|
eicosapentaenoic acid - blood |
1 |
|
eicosapentaenoic acid - therapeutic use |
1 |
|
endothelial damage |
1 |
|
endothelium |
1 |
|
endothelium, vascular - physiopathology |
1 |
|
england |
1 |
|
enzyme-linked immunosorbent assay - methods |
1 |
|
epoprostenol - administration & dosage - adverse effects - analogs & derivatives - therapeutic use |
1 |
|
epoprostenol - administration & dosage - analogs & derivatives - pharmacology - therapeutic use |
1 |
|
epoprostenol - adverse effects - analogs & derivatives - pharmacology |
1 |
|
erythrocyte deformability - drug effects |
1 |
|
erythrocyte membrane - metabolism |
1 |
|
erythrocytes - immunology |
1 |
|
estradiol - blood |
1 |
|
estrogens - adverse effects - therapeutic use |
1 |
|
ethics |
1 |
|
ethnicity |
1 |
|
etidronic acid - administration & dosage - analogs & derivatives - therapeutic use |
1 |
|
etidronic acid - adverse effects - analogs & derivatives - therapeutic use |
1 |
|
etidronic acid - analogs and derivatives - pharmacology - therapeutic use |
1 |
|
european continental ancestry group - genetics |
1 |
|
evolution, molecular |
1 |
|
factor viii - metabolism |
1 |
|
family |
1 |
|
family practice |
1 |
|
far east |
1 |
|
fatty acids - analysis |
1 |
|
fatty acids - blood |
1 |
|
fatty acids, omega-3 - adverse effects - therapeutic use |
1 |
|
fatty acids, omega-3 - analysis |
1 |
|
femoral artery |
1 |
|
fever |
1 |
|
fibrinogen - analysis |
1 |
|
fibrinolysis - drug effects |
1 |
|
fibrinolysis - physiology |
1 |
|
fibrinopeptide a - analysis |
1 |
|
filtration - methods |
1 |
|
fingers |
1 |
|
fingers - blood supply |
1 |
|
fish oils - administration & dosage - adverse effects - therapeutic use |
1 |
|
fish oils - adverse effects - therapeutic use |
1 |
|
fish oils - pharmacology |
1 |
|
fish oils - therapeutic use |
1 |
|
flare |
1 |
|
fluorescent antibody technique |
1 |
|
fluorescent antibody technique, indirect |
1 |
|
follicle stimulating hormone - blood |
1 |
|
free radicals |
1 |
|
free radicals - metabolism |
1 |
|
gastrointestinal |
1 |
|
gastrointestinal hemorrhage - chemically induced |
1 |
|
gene frequency - genetics |
1 |
|
genetic linkage - genetics |
1 |
|
genetic variation |
1 |
|
genetics, population |
1 |
|
genotyping |
1 |
|
geriatric patient |
1 |
|
glomerulonephritis |
1 |
|
glucocorticoids |
1 |
|
glucocorticoids - administration & dosage |
1 |
|
glucocorticoids - administration & dosage - adverse effects |
1 |
|
glucocorticoids - adverse effects - pharmacology - therapeutic use |
1 |
|
glucosamine |
1 |
|
glucosamine - adverse effects - therapeutic use |
1 |
|
gonadal steroid hormones - blood |
1 |
|
graft vs host disease - immunology |
1 |
|
haemodialysis |
1 |
|
health care manpower |
1 |
|
health care organization |
1 |
|
health expenditures |
1 |
|
health knowledge, attitudes, practice |
1 |
|
heart rate - drug effects |
1 |
|
hematologic diseases - complications |
1 |
|
hemodialysis (hd) |
1 |
|
hemolytic plaque technique |
1 |
|
hepatosplenomegaly |
1 |
|
high disease activity |
1 |
|
hla-dr4 antigen - genetics |
1 |
|
holistic |
1 |
|
home hemodialysis (hd) |
1 |
|
human |
1 |
|
hyperprolactinaemia |
1 |
|
hyperprolactinemia - blood |
1 |
|
hypertension - chemically induced |
1 |
|
hypertension, pulmonary - complications |
1 |
|
hypertrophy |
1 |
|
hypogonadism |
1 |
|
hypogonadism - blood |
1 |
|
idiosyncratic reaction |
1 |
|
igm |
1 |
|
iloprost - adverse effects - pharmacology |
1 |
|
iloprost - adverse effects - therapeutic use |
1 |
|
imidazoles - administration & dosage - therapeutic use |
1 |
|
imidazoles - adverse effects - therapeutic use |
1 |
|
imidazoles - pharmacology - therapeutic use |
1 |
|
immune system - drug effects |
1 |
|
immunocompromised hosts |
1 |
|
immunoenzyme techniques |
1 |
|
immunosuppressants |
1 |
|
immunosuppressive |
1 |
|
immunosuppressive agents - administration & dosage |
1 |
|
immunosuppressive agents - administration & dosage - therapeutic use |
1 |
|
implementation |
1 |
|
infant |
1 |
|
infection - mortality |
1 |
|
inflammatory arthritis |
1 |
|
infusions, intravenous |
1 |
|
injections, intravenous |
1 |
|
integrin |
1 |
|
interleukin-10 - genetics - immunology |
1 |
|
international cooperation |
1 |
|
intraoperative anaphylaxis |
1 |
|
itgam |
1 |
|
joint diseases - complications |
1 |
|
juvenile rheumatoid arthritis |
1 |
|
kidney failure, chronic - blood |
1 |
|
kidney failure, chronic - complications - therapy |
1 |
|
kidney failure, chronic - drug therapy |
1 |
|
large vessel |
1 |
|
laser-doppler flowmetry |
1 |
|
lasers - diagnostic use |
1 |
|
least-squares analysis |
1 |
|
length of stay - statistics & numerical data |
1 |
|
leprostatic agents - adverse effects |
1 |
|
letter |
1 |
|
leukocyte count |
1 |
|
leukocytes - metabolism |
1 |
|
leukocytosis |
1 |
|
leukotriene b4 - biosynthesis |
1 |
|
leukotrienes |
1 |
|
liver diseases - complications |
1 |
|
liver dysfunction |
1 |
|
liver function tests |
1 |
|
low-income |
1 |
|
lumbar vertebrae - physiopathology |
1 |
|
lunate bone - injuries - pathology - radiography |
1 |
|
lupus erythematosus, cutaneous - drug therapy |
1 |
|
lupus erythematosus, cutaneous - drug therapy - pathology |
1 |
|
lupus erythematosus, systemic - blood - drug therapy |
1 |
|
lupus erythematosus, systemic - blood - drug therapy - pathology |
1 |
|
lupus erythematosus, systemic - blood - genetics - metabolism |
1 |
|
lupus erythematosus, systemic - blood - pathology |
1 |
|
lupus erythematosus, systemic - blood - physiopathology |
1 |
|
lupus erythematosus, systemic - chemically induced - physiopathology |
1 |
|
lupus erythematosus, systemic - complications - diagnosis - immunology |
1 |
|
lupus erythematosus, systemic - complications - drug therapy - pathology |
1 |
|
lupus erythematosus, systemic - complications - mortality |
1 |
|
lupus erythematosus, systemic - drug therapy - epidemiology - physiopathology |
1 |
|
lupus erythematosus, systemic - drug therapy - immunology - psychology |
1 |
|
lupus erythematosus, systemic - economics - physiopathology |
1 |
|
lupus erythematosus, systemic - epidemiology - genetics - immunology |
1 |
|
lupus erythematosus, systemic - epidemiology - physiopathology |
1 |
|
lupus erythematosus, systemic - ethnology - immunology - mortality |
1 |
|
lupus erythematosus, systemic - ethnology - therapy |
1 |
|
lupus erythematosus, systemic - immunology |
1 |
|
lupus erythematosus, systemic - physiopathology |
1 |
|
lupus erythematosus, systemic/immunology |
1 |
|
lupus nephritis - complications - drug therapy - ethnology - pathology |
1 |
|
lupus nephritis - drug therapy - ethnology |
1 |
|
lupus nephritis - ethnology - immunology - mortality |
1 |
|
lupus nephritis - genetics - immunology |
1 |
|
lupus vasculitis, central nervous system - epidemiology - psychology |
1 |
|
luteinizing hormone - blood |
1 |
|
lymphocyte activation |
1 |
|
lymphocytes - metabolism |
1 |
|
lymphocytes - metabolism - pathology |
1 |
|
macrovascular disease |
1 |
|
malondialdehyde - blood |
1 |
|
malondialdehyde - metabolism |
1 |
|
measles |
1 |
|
measles - diagnosis - virology |
1 |
|
measles virus - classification - genetics - isolation and purification |
1 |
|
medical education |
1 |
|
medical literature |
1 |
|
medical research |
1 |
|
medline |
1 |
|
meningitis, bacterial - complications - diagnosis |
1 |
|
menopause |
1 |
|
menopause - physiology |
1 |
|
menstruation |
1 |
|
meta-regression |
1 |
|
methylprednisolone - therapeutic use |
1 |
|
middle-income |
1 |
|
mixed connective tissue disease - diagnosis - drug therapy - physiopathology |
1 |
|
models of care |
1 |
|
mok, c.c. |
1 |
|
molecular sequence data |
1 |
|
mononuclear phagocyte system - pathology |
1 |
|
musculoskeletal |
1 |
|
mycophenolate |
1 |
|
mycophenolic acid - analogs & derivatives - therapeutic use |
1 |
|
myelitis |
1 |
|
myelitis, transverse - diagnosis - drug therapy - etiology - immunology |
1 |
|
myelitis, transverse - diagnosis - drug therapy - physiopathology |
1 |
|
myelitis, transverse - drug therapy - etiology - pathology |
1 |
|
myelodysplastic syndromes - complications |
1 |
|
naproxen |
1 |
|
natural selection |
1 |
|
nephritis |
1 |
|
nephritis - etiology |
1 |
|
neurologic examination - drug effects |
1 |
|
neurological |
1 |
|
neutrophils - cytology - physiology |
1 |
|
nocardia infections - complications - diagnosis |
1 |
|
nocardiosis |
1 |
|
nocturnal hemodialysis (hd) |
1 |
|
nsaid |
1 |
|
nsaids |
1 |
|
nutrition disorders - etiology - prevention & control |
1 |
|
occupational diseases - metabolism |
1 |
|
oils - analysis - therapeutic use |
1 |
|
organ damage accrual |
1 |
|
osteoarthritis - diagnosis - epidemiology - therapy |
1 |
|
osteoarthritis - drug therapy |
1 |
|
osteoarthritis - drug therapy - epidemiology |
1 |
|
osteochondritis - complications - etiology - radiography |
1 |
|
osteoporosis - chemically induced - drug therapy |
1 |
|
osteoporosis - chemically induced - drug therapy - physiopathology - prevention & control |
1 |
|
osteoporosis, postmenopausal - chemically induced - drug therapy - physiopathology - prevention & control |
1 |
|
outcome assessment, health care |
1 |
|
outcomes |
1 |
|
outcomes research |
1 |
|
ovary - drug effects |
1 |
|
pacific islands |
1 |
|
pan troglodytes - genetics |
1 |
|
panniculitis, nodular nonsuppurative - complications - pathology |
1 |
|
paramedical personnel |
1 |
|
parents |
1 |
|
parvoviridae infections - diagnosis - epidemiology - immunology |
1 |
|
parvovirus b19, human - immunology |
1 |
|
patient centred |
1 |
|
patient reported outcome measure (prom) rheumatology key messages |
1 |
|
pdas |
1 |
|
peptic ulcer - chemically induced - diagnosis - epidemiology |
1 |
|
periodicals as topic |
1 |
|
periodicity |
1 |
|
peripheral blood lymphocytes |
1 |
|
peripheral vascular disease |
1 |
|
peripheral vascular diseases - blood |
1 |
|
peripheral vascular diseases - therapy |
1 |
|
pharmacovigilance |
1 |
|
pharyngitis - complications |
1 |
|
phosphodiesterase inhibitors - therapeutic use |
1 |
|
physician's practice patterns |
1 |
|
pilot projects |
1 |
|
piperazines - therapeutic use |
1 |
|
pituitary diseases - complications - pathology |
1 |
|
plaque-forming cells |
1 |
|
plasminogen activator inhibitor-1 |
1 |
|
plasminogen inactivators - blood |
1 |
|
platelet activation |
1 |
|
platelet aggregation |
1 |
|
platelet aggregation - drug effects |
1 |
|
platelet aggregation - drug effects - physiology |
1 |
|
platelet aggregation inhibitors - pharmacology |
1 |
|
platelet count |
1 |
|
pokeweed mitogens - immunology |
1 |
|
policy making |
1 |
|
poly-l-lysine |
1 |
|
polylysine - immunology |
1 |
|
polymerase chain reaction |
1 |
|
polymeric prodrugs |
1 |
|
polymorphism evolution |
1 |
|
polymorphism, restriction fragment length |
1 |
|
polymorphonuclear cell aggregation |
1 |
|
polymyalgia rheumatica - etiology |
1 |
|
polymyositis - complications - pathology |
1 |
|
popliteal artery |
1 |
|
population study |
1 |
|
postmenopause - metabolism |
1 |
|
posttranslational modification (ptm) |
1 |
|
practice guidelines as topic |
1 |
|
predictive value of tests |
1 |
|
prednisone - administration & dosage |
1 |
|
prednisone - administration & dosage - adverse effects |
1 |
|
premenopause |
1 |
|
pressure |
1 |
|
primary ovarian insufficiency - blood - chemically induced - physiopathology |
1 |
|
primary ovarian insufficiency - chemically induced |
1 |
|
primary sjogren's syndrome (pss) |
1 |
|
priority journal |
1 |
|
prognostic indicators |
1 |
|
prolactin |
1 |
|
prolactin - blood |
1 |
|
prolactin - blood - drug effects |
1 |
|
proteinuria |
1 |
|
proto-oncogene proteins c-bcl-2 - biosynthesis |
1 |
|
psychiatric |
1 |
|
psychotic disorders - etiology |
1 |
|
puerperal disorders - physiopathology |
1 |
|
pulmonary fibrosis - complications - mortality |
1 |
|
pyrexia |
1 |
|
qualitative |
1 |
|
ra |
1 |
|
radioimmunoassay |
1 |
|
randomized controlled trials as topic |
1 |
|
randomized controlled trials as topic - methods |
1 |
|
raynaud disease - blood |
1 |
|
raynaud disease - blood - complications - metabolism |
1 |
|
raynaud disease - blood - immunology |
1 |
|
raynaud disease - blood - physiopathology |
1 |
|
raynaud disease - drug therapy - etiology |
1 |
|
raynaud disease - etiology - metabolism |
1 |
|
raynaud disease - etiology - physiopathology |
1 |
|
raynaud disease - physiopathology |
1 |
|
raynaud's syndrome |
1 |
|
raynaud's-systemic sclerosis |
1 |
|
receptors, interleukin - blood |
1 |
|
receptors, prostaglandin - antagonists & inhibitors |
1 |
|
receptors, thromboxane |
1 |
|
red cell deformability |
1 |
|
regional blood flow |
1 |
|
regional blood flow - drug effects |
1 |
|
regional blood flow - physiology |
1 |
|
regulatory region |
1 |
|
remission |
1 |
|
remission induction |
1 |
|
remission, spontaneous |
1 |
|
renal dialysis |
1 |
|
renal dialysis - economics - methods - mortality - standards |
1 |
|
renal failure |
1 |
|
renal osteodystrophy - etiology - prevention & control |
1 |
|
reperfusion |
1 |
|
rheumatic disease |
1 |
|
rheumatic diseases |
1 |
|
rheumatic diseases - diagnosis - therapy |
1 |
|
rheumatic diseases - therapy |
1 |
|
rheumatoid factor - blood |
1 |
|
rheumatology - education |
1 |
|
rheumatology - education - trends |
1 |
|
rheumatology - trends |
1 |
|
ribonucleoproteins, small nuclear - chemistry - immunology |
1 |
|
ribosomal proteins/immunology |
1 |
|
risedronate |
1 |
|
rofecoxib |
1 |
|
ros-responsive nanoparticles |
1 |
|
rt-pcr |
1 |
|
scleroderma, systemic - blood |
1 |
|
scleroderma, systemic - complications |
1 |
|
scleroderma, systemic - complications - physiopathology |
1 |
|
scleroderma, systemic - metabolism |
1 |
|
scotland |
1 |
|
seasonal variation |
1 |
|
seizures - epidemiology |
1 |
|
selection, genetic |
1 |
|
sex factors |
1 |
|
sex hormones |
1 |
|
sheep |
1 |
|
siblings |
1 |
|
skin - blood supply |
1 |
|
skin diseases - blood - immunology |
1 |
|
skin diseases - complications |
1 |
|
skin test |
1 |
|
sledai |
1 |
|
smoking - blood |
1 |
|
snakes |
1 |
|
south africa |
1 |
|
specific ige |
1 |
|
spinal cord - drug effects - physiopathology |
1 |
|
spinal cord - pathology |
1 |
|
staphylococcus aureus - immunology |
1 |
|
steroids - adverse effects - therapeutic use |
1 |
|
still's disease, adult-onset - complications - drug therapy - epidemiology |
1 |
|
sulfhydryl compounds - blood |
1 |
|
sulfone |
1 |
|
survival analysis |
1 |
|
symptom |
1 |
|
systemic lupus erythromatosis |
1 |
|
t cell |
1 |
|
targeted therapy |
1 |
|
testosterone - blood |
1 |
|
thrombocytopenia - epidemiology - immunology |
1 |
|
thrombocytopenia - etiology - mortality |
1 |
|
thromboembolism - chemically induced |
1 |
|
thrombosis - chemically induced |
1 |
|
thrombosis - etiology |
1 |
|
thromboxane |
1 |
|
thromboxane receptor antagonist |
1 |
|
tissue plasminogen activator - blood |
1 |
|
toes - blood supply |
1 |
|
toxicity |
1 |
|
transplantation |
1 |
|
transverse myelopathy |
1 |
|
treatment |
1 |
|
treatment failure |
1 |
|
ulcerative colitis |
1 |
|
ulcers |
1 |
|
united kingdom |
1 |
|
vasculitis |
1 |
|
vasculitis - blood - etiology |
1 |
|
vasculitis - blood - etiology - physiopathology |
1 |
|
vasoconstriction |
1 |
|
vasodilation |
1 |
|
vasodilation - physiology |
1 |
|
vasodilator agents - pharmacology |
1 |
|
vasospasm |
1 |
|
vasospastic disease |
1 |
|
vibration - adverse effects |
1 |
|
vibration white finger disease |
1 |
|
virology - methods |
1 |
|
virus disease 2019 |
1 |
|
virus isolation |
1 |
|
vitamin d - analogs & derivatives - blood |
1 |
|
von willebrand factor - analysis |
1 |
|
von willebrand factor - metabolism |
1 |
|
water-electrolyte balance |
1 |
|
young adult |
1 |
|
zoledronic acid |
1 |
